| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
32,633,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
1,434,166 |
Avg
Vol: |
647,896 |
| 52
Week Range: |
$21.74 - $21.74 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2013-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,200 |
2,759,650 |
|
- |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-02-22 |
4 |
S |
$8.18 |
$8,049 |
D/D |
(984) |
63,758 |
|
- |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-02-22 |
4 |
S |
$8.18 |
$8,049 |
D/D |
(984) |
35,886 |
|
- |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-02-19 |
4 |
S |
$7.89 |
$7,890 |
D/D |
(1,000) |
36,870 |
|
- |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2013-01-31 |
4 |
A |
$5.99 |
$59,900 |
D/D |
10,000 |
37,870 |
|
- |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2013-01-31 |
4 |
A |
$5.99 |
$59,900 |
D/D |
10,000 |
64,742 |
|
- |
|
| Nolan Michael M |
VP, CFO and Treasurer |
• – – |
2013-01-31 |
4 |
A |
$5.99 |
$79,865 |
D/D |
13,333 |
63,333 |
|
- |
|
| Henderson Lori M |
VP, general counsel |
• – – |
2013-01-31 |
4 |
A |
$5.99 |
$69,879 |
D/D |
11,666 |
49,440 |
|
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2013-01-31 |
4 |
A |
$5.99 |
$159,729 |
D/D |
26,666 |
2,769,850 |
|
- |
|
| Leung Gabriel |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
25,321 |
|
- |
|
| Oconnor Kevin |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
30,420 |
|
- |
|
| Roth Arthur J |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
33,104 |
|
- |
|
| Ryan Una S |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
26,084 |
|
- |
|
| Jordan Veronica Gh |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
29,147 |
|
- |
|
| Marth William S |
Director |
– • – |
2013-01-31 |
4 |
A |
$5.99 |
$35,000 |
D/D |
5,843 |
28,291 |
|
- |
|
| Dambra Geoffrey |
10% Owner |
– – • |
2012-12-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
375,000 |
|
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2012-12-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
375,000 |
2,743,184 |
|
- |
|
| D Ambra Constance M |
10% Owner |
– – • |
2012-12-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
375,000 |
2,696,518 |
|
- |
|
| Marth William S |
Director |
– • – |
2012-12-03 |
4 |
B |
$5.00 |
$50,000 |
D/D |
10,000 |
22,448 |
2.39 |
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2012-11-15 |
4 |
B |
$3.80 |
$38,000 |
D/D |
10,000 |
3,118,184 |
3.23 |
- |
|
| D Ambra Constance M |
10% Owner |
– – • |
2012-11-15 |
4 |
B |
$3.80 |
$38,000 |
D/D |
10,000 |
3,071,518 |
2.37 |
- |
|
| Hagen Steven R |
Sr VP Pharmaceutical Dev & Mfg |
• – – |
2012-11-05 |
4 |
S |
$3.51 |
$1,306 |
D/D |
(372) |
27,870 |
|
- |
|
| Nolan Michael M |
VP, CFO and TreasurerOfficer |
• – – |
2012-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,000 |
|
- |
|
| Frost Mark T |
Chief Financial Officer |
• – – |
2012-09-14 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,666) |
62,933 |
|
- |
|
| Cable Stuart M |
10% Owner |
– – • |
2012-09-06 |
5 |
GA |
$0.00 |
$0 |
I/I |
1,500,000 |
4,565,189 |
|
- |
|
620 Records found
|
|
Page 16 of 25 |
|
|
